Gene delivery into dendritic cells (DC) is most efficiently achieved by viral vectors. Recombinant canarypox viruses (ALVAC) were validated safe and efficient in humans. We aimed firstly to evaluate DC transduction by ALVAC vectors, then to investigate if such infection induced or not the maturation of the DC, and finally to assess the efficiency of ALVAC-MAGE-transduced DC to activate specific CTL clones. Clinical grade DC from melanoma patients were generated from blood monocytes and infected with a recombinant ALVAC virus encoding either a marker gene (EGFP) or the MAGE-1-MAGE-3 minigenes. According to the patientdonor, 22716% of immature DC were successfully transduced. Flow cytometry analysis of surface markers expressed on DC after ALVAC infection did not reveal a mature phenotype. Moreover, ALVAC transduction did not interfere with the capacity of the DC to further mature under poly:IC stimulation. But most importantly, our results demonstrated that DC from HLA-A1 patient-donors infected with the recombinant ALVAC MAGE-1-MAGE-3 minigenes virus were capable of activating a MAGE 3/A1 CTL clone more efficiently than same DC loaded with MAGE 3/A1 peptide, as shown by increased IFN-g secretion. These results could be the basis for the development of a new clinical strategy in melanoma patient's immunotherapy.
T argeting identified tumor-associated antigens (TAA) to dendritic cells (DC) has become the basis of various vaccination strategies in order to obtain an immune control of tumor growth. DC are considered the most potent antigen-presenting cells (APC) due to their ability to induce strong T-cell responses, even of naive T cells. Recent clinical trials using DC loaded with MHC class-I-specific synthetic peptides or with whole tumor cell lysate preparations [1] [2] [3] [4] have demonstrated that DC-based active immunization has no major toxicity in the vaccinated patients, but results in tumor regression in only a minority of them. Indeed tumor-specific T-cell responses were induced and detected in vitro but, unfortunately, they were often only transient. The overall results of these trials revealed the need for improved DCbased vaccines before they become an optimal commonly used modality for the treatment of cancer.
Transferring TAA genes into DC might have a number of potential advantages over other methods of antigen delivery. Transduced DC may be able to constitutively express and process TAA to produce long-term antigen presentation in vivo. Moreover, they may be able to present multiple identified or yet undefined MHC class I and II epitopes without allelic HLA restriction and so efficiently stimulate antitumour responses which possibly involve CD8 þ cytotoxic and CD4 þ helper T cells. 5 Other advantage is the possibility of adding sequences coding for various immunomodulators (like cytokines or costimulatory molecules) that could enhance the immune response. Several methods of gene transfer into DC have been reported using either physical methods including liposome complexes or electroporation 6, 7 or viral vectors. [8] [9] [10] [11] [12] The transduction of human monocytes-derived DC seems to be more efficient by using viral vectors. DC transduced with recombinant adenovirus, 7, 11, [13] [14] [15] retrovirus, 16 or vaccinia virus 10, 17 have proved to be effective in inducing CTL responses and protection against tumors. However, some of these viral vectors can disturb the function of DC as APC. [18] [19] [20] [21] ALVAC recombinant virus were derived from a highly attenuated canarypox virus that does not replicate in mammalian cells, the production of infectious progeny virus being limited to avian species. 22, 23 They are appealing for gene therapy for several reasons. Firstly, they are able to infect a wide variety of cell types with high efficiencies of infection. 24 In addition, abortive replication of ALVAC vectors in infected mammalian cells does not preclude expression of the inserted foreign genes. 25 Finally, the safety and immunogenicity of ALVAC vectors have been validated in humans within diverse infectious diseases trials or cancer trials. [26] [27] [28] Besides, successful identification of new antigens of the melanoma antigen (MAGE) family, 29, 30 more precisely the ones encoded by the MAGE-A1 gene resulted from the in vitro stimulation of blood-derived DC from normal donors with an ALVAC recombinant virus containing the entire MAGE-A1 gene. 31 The same study coincidentally reported that the procedure was efficient for the activation of anti-MAGE CTL precursors, allowing the isolation of permanent anti-MAGE CTL clones.
The aims of this study were firstly to evaluate the efficiency of ALVAC recombinant vectors to transduce clinical grade DC derived from cancer patients, especially melanoma patients, then to investigate if such infection could induce or not induce the maturation of the DC, and finally to assess comparatively in vitro the potency of ALVAC-MAGE-transduced DC versus MAGE peptidepulsed DC to activate specific CTL clones.
Materials and methods

DC generation
Clinical grade DC were generated in a closed system (Cell Culture Container PL2417, Nexell Therapeutics, Irvine, CA) from peripheral blood monocytes of melanoma patients included in DC vaccination clinical protocols as previously described. 4 Briefly, peripheral blood mononuclear cells (PBMC) were obtained by leukapheresis on a COBE SPECTRA separator (Cobe, Denver, CO). The monocytes-enriched fraction, resulting from a modifiedadherence step in the culture bag, was seeded for 7 days in a serum-free medium (X-VIVO 20, Bio-Whittaker, Walkersville, MD) supplemented with 800 U/ml GM-CSF (Leukomax, Novartis, Basel, Switzerland) and 1000 U/ ml IL-4 (Schering-Plough, Kenilworth, NJ). DC purity was checked and evaluated by morphological analysis (May Grunwald Giemsa staining) and flow cytometry using specific antibodies directed against DC markers (CD1a and HLA-DR), monocyte marker (CD14), T-cell marker (CD3), B-cell marker (CD19) and NK markers (CD16 þ 56). According to patient donor, DC yield reached 70716% with a minimum of 45% and a maximum of 95%. Unless otherwise stated, experiments were performed using DC derived with this procedure, which typically gives immature DC. They were utilized either fresh or were kept frozen at À801C, and were thawed the day of the experiment. To generate mature DC, nonadherent immature DC were cultured before or after infection by ALVAC vectors, during 48 or 72 hours, in the presence of LPS (1 or 5 mg/ml; Sigma-Aldrich, Bornem, Belgium) or poly I:C (20 mg/ml, Roche Diagnostics, Brussels, Belgium), respectively.
Recombinant ALVAC viruses and infection of dendritic cells
The recombinant canarypox ALVAC-EGFP (vCP1540) and ALVAC-MAGE-1-MAGE-3 CTL epitopes (minigenes) (vCP1469a) were developed by Pasteur-Merieux Connaught (Lyon, France) and produced by Virogenetics Corporation (Troy, USA). Viral stocks contained different amounts of plaque-forming units (PFU): 1.9 Â 10 9 and 3.0 Â 10 9 PFU/ml respectively. Viral vectors were added to the DC (2 Â 10 6 cells/ ml X-VIVO 20 medium) at various multiplicity of infection (MOI 5, 10, 15, 20, 30) . The MOI was calculated as a number of PFU/cell, considering the total number of cells in the sample, independently of the real number of DC. The infection was conducted at 371C for different times (1, 2, 6 hours) following which the infected DC were washed twice in X-VIVO 20 medium. Infected DC were then recultured for 24 hours or more when specified. Efficiency of gene transduction was assessed by measuring EGFP expression by flow cytometry within an FSC/SSC region focused on DC, as testified by the fact that at least 90% of cells in the gate expressed the CD1a and HLA-DR surface markers. The DC mortality was evaluated by propidium iodide (PI) staining.
DC phenotype
The phenotype of ALVAC-infected dendritic cells was analysed by flow cytometry using different phycoerythrin (PE)-conjugated antibodies specific of characteristic surface antigens: CD1a, HLA-DR, CD40, CD80, CD83, CD86. Briefly, cells were incubated with antibodies for 30 minutes at 41C, then washed twice and analysed by flow cytometry using a FACScan (Becton Dickinson) and the Cell Quest software.
CTL activation assays
DC generated from HLA-A1 cancer patients were infected with an ALVAC-MAGE-1-MAGE-3 (minigenes) recombinant vector at different MOI (5, 10, 20) for 1 or 2 hours, then washed and distributed in round-bottomed 96 wells plates at 3 Â 10 4 cells/well/50 ml. A total of 10,000 cells of the CTL clone 82/30, specific for the MAGE1-A1 epitope or of the CTL-clone 20/38 specific for the MAGE3-A1 epitope (kind gift from P van der Bruggen, Ludwig Institute, Brussels) were then added to ALVACtransduced DC. After 24 hours stimulation at 371C in presence of recombinant IL-2 (25 U/ml), culture supernatants were harvested and tested for IFN-g content by ELISA. DC pulsed with relevant MAGE1-A1 or MAGE3-A1 peptides were also used in parallel as stimulators. Pulsing was carried out by incubating 2 Â 10 6 cells/ ml for 2 hours at 371C with 50 mg/ml peptide as previously described. 4 We used as negative controls for CTL activation nontransduced DC or ALVAC-EGFP-transduced DC and as positive control DC cocultured with the MEL-Z2 melanoma cell line.
Cytokine determination
Determination of IL-12 p40 production, IFN-g production or IL-10 production was done in culture supernatants using ELISA kits purchased from Biosource Europe (Fleurus, Belgium) following the manufacturer's instructions.
Statistics
Statistical analysis were performed using the unpaired t-test with 95% confidence interval.
Results
Optimization of DC-ALVAC infection protocol
We first determined the optimal ALVAC infection conditions for melanoma patients-derived immature DC generated in vitro from adherent blood monocytes by 7 days culture in X-VIVO 20 medium supplemented with GM-CSF and IL-4 as described in Toungouz et al. 4 We therefore checked the viability/mortality and the expression of a marker transgene (EGFP, enhanced green fluorescent protein) after infection with an ALVAC recombinant virus carrying the EGFP gene, as function of MOI and duration of infection. The cells (2 Â 10 6 cells/ ml X-VIVO 20 medium) were submitted to infection at MOI 5, 10, 15, 20, 30 PFU/cell for 1, 2 or 6 hours, washed, recultured for another 20 hours in X-VIVO 20 medium in presence of IL-4 and GM-CSF and then tested by flow cytometry for EGFP expression. As a positive control of infection, we infected 2 Â 10 6 cells/1 ml complete RPMI 1640 supplemented with 10% FCS with ALVAC-EGFP at MOI 30 for 2 hours as done in Chaux et al. 31 Data from pilot experiments (not shown) demonstrated that the DC EGFP expression already reached a plateau after 1 hour infection at MOI 10. The percentage of cells transduced was not augmented by the use of higher MOI (20 or 30) or longer infection duration (2 or 6 hours). On the contrary, the DC mortality which was limited and similar for the DC kept nontreated in culture or infected with ALVAC vector at MOI 10 for 1 hour, increased to worse with higher MOI (30) and longer infection duration (6 hours). Therefore, the infection protocol chosen for further studies was thus 1 hour infection at MOI 10.
ALVAC vectors successfully infect immature DC without changing their phenotype
We thereafter tested the variability in cancer patientsderived DC transduction by ALVAC. As shown in Figure 1 , 5-60% (mean7SD: 22.5716.1) of immature DC generated from cancer patients were successfully infected by an ALVAC recombinant vector carrying the EGFP gene. Variability in EGFP expression was observed according to the patient-donor (n ¼ 10) or repetitive experiments within same patient-donor (donor D/D 0 ). We also checked if infection by ALVAC recombinant virus resulted in DC maturation. Expression of classical surface markers on DC after infection with ALVAC-EGFP was tested by flow cytometry using a two-step gating procedure: the first focusing DC within a FSC/SSC region, as testified by the expression of the CD1a and HLA-DR markers; the second targeting EGFP positive DC. Pooled data from five different donors did not reveal a mature phenotype when compared to control noninfected DC tested at the same day (Fig 2) . Indeed, even if slight increases in the expression of DR and CD86 molecules were detectable, those were not statistically significant (P ¼ .08 and .22, respectively). Moreover, the CD83 molecule whose expression is characteristic of a 
ALVAC-MAGE
mature DC phenotype was never expressed. Consistently, as illustrated in Figure 5 , no or low IL-12 secretion was detected in DC culture supernatants after ALVAC infection.
Immature DC infected by ALVAC vectors are still able to mature DC maturation is a crucial step in inducing adaptive immunity. By controlling as a prerequisite the capacity of immature DC generated in serum-free X-VIVO 20 medium to mature under stimulation by different agents, we have observed that no maturation was induced when DC were treated by LPS, even for 48 hours at 5 mg/ml (Fig  3a) . However, a 72-hour incubation of same DC with poly I:C at 20 mg/ml resulted in maturation as reflected by the increased expression of the costimulatory markers and the slight expression of the CD83 (Fig 3b) . We thereafter checked if it was still possible to induce the maturation of DC previously infected by ALVAC recombinant virus. Flow cytometry analysis was conducted using the two-step gating procedure, as described previously. Results from one representative experiment (Fig 4) showed an upregulation of the costimulatory markers DR, CD40, CD80, CD86 as well as the slight upregulation of the CD83 marker. Immature ALVACinfected DC thus still kept the capacity to mature in response to the addition of poly I:C. We also observed by using an ALVAC-EGFP recombinant virus that poly I:C matured DC were infected with an about 10% lower efficacy than immature ones (data not shown).
DC infected by ALVAC vector and matured with poly I:C secrete IL12
All DC culture supernatants from the various maturation and ALVAC transduction experiments were tested by ELISA for IL12 p40 production. Data from Figure 5 show a highly increased IL-12 secretion by DC treated with poly I:C (mean7SD: 314173562) as compared to the low amount of IL-12 produced by immature noninfected DC (mean7SD: 67737) or by ALVACtransduced DC (mean7SD: 4070). Furthermore when DC were infected by ALVAC prior to poly I:C treatment, they still secreted high amounts of IL-12 p40 (mean7SD: 217672512). Besides, IL-10 secretion by the DC was negligible (o10 pg/ml) in basal condition and not modulated after ALVAC infection (data not shown).
Enhanced activation of a MAGE 3/A1 CTL clone by DC transduced by ALVAC-MAGE-1-MAGE-3 minigenesvector
We finally evaluated comparatively the potency of ALVAC-transduced DC versus peptide-pulsed DC to activate specifically CTL clones. Two different CTL clones restricted respectively for MAGE 1/A1 (data not shown) or MAGE 3/A1 tumor antigens were tested under stimulation by DC from HLA-A1 patient-donors transduced by an ALVAC vector carrying MAGE-1/A1 and MAGE-3/A1 minigenes. DC pulsed with relevant MAGE1-A1 (data not shown) or MAGE3-A1 peptides were also used in parallel as stimulators. We used as Figure 6a -c demonstrated that DC from HLA-A1 patient-donors transduced with ALVAC vectors carrying MAGE 1-MAGE 3 minigenes were capable of activating a MAGE 3/A1 CTL clone more efficiently than same DC loaded with MAGE 3/A1 peptide, as shown by increased IFN-g secretion. Quite interestingly, clear enhanced CTL activation was also obtained by stimulation with a DC population that had been infected by the ALVAC-MAGE-1-MAGE-3 minigenes vector with a low efficiency of transduction (as measured at same time following infection of same DC with the ALVAC-EGFP viral vector), that is, score of 5% for donor S.
Discussion
The aim of this study was to characterize carefully the transduction of DC derived from melanoma patients by an ALVAC vector as a prerequisite for future clinical vaccination trials using DC genetically modified to present products of MAGE 1 and MAGE 3 minigenes. We thus firstly optimized the infection procedure of clinical grade DC by ALVAC recombinant virus and then showed that ALVAC vectors were capable of infecting immature DC without inducing their maturation. However, ALVAC transduction did not interfere with the Since DC have a relatively unstable phenotype, nonperturbing methods of gene transfer should be employed so that their viability and their immunostimulatory capacity are not compromised. As we showed, these requirements were satisfied by ALVAC recombinant virus. On the contrary, vaccinia virus (VV) and especially herpes simplex virus (HSV) which has a strong cytopathogenic effect on immature DC 32 inhibit DC maturation 33, 34 and efficient antigen presentation by selectively downregulating expression of MHC class I/II, CD 80 and CD 83 molecules 32, [35] [36] [37] or by interfering with the TAP-loading mechanism. 19 We described in this report that ALVAC vectors were efficiently capable of infecting clinical-grade immature DC, but not with same efficacy mature DC (data not shown). These results are partly in contradiction with studies reporting important induction of apoptosis within ALVAC-infected immature DC. [38] [39] [40] But it is likely that the protocol we set up to infect those DC (MOI 10, 1 hour of infection) was better for having good recombinant protein expression without inducing high mortality or apoptotic cell death. On the other hand, the fact that mature DC are more resistant to ALVAC infection was also reported by same authors.
Our data show no real maturation of DC induced by ALVAC infection since the ''maturation marker'' CD83 was not expressed at the DC surface although there was a slight upregulation of MHC-II and the CD86 molecules. Moreover, IL-12 production was as low as in noninfected DC. These results are in contradiction with the papers of Motta et al 39 and Marovich et al 40 which are suggesting or showing that infection of DC by canarypox viruses led to their maturation. They indeed observed that the expression of MHC-II, CD40, CD80 and CD86 antigens was upregulated and expression of CD83 induced. However, both studies used DC cultured in medium supplemented with serum (FCS or autologous plasma) whereas we generated and transduced DC in serum free X-VIVO 20 medium where it was quite more difficult to induce DC maturation (as shown in Fig 3) . Besides, we have compared MHC-II, CD40, CD80, CD83 and CD86 expression between ALVAC-infected DC and control noninfected DC at same time-point, that is, after 24 hours or more of reculture, which is rarely done and could be the source of misinterpretation. Indeed, as shown in Figure 2 , there is a notable increase in the DR or CD86 expression in control noninfected DC after 1 day reculture.
However, ALVAC does not interfere with the capacity of DC to mature following a poly I:C stimulus. We indeed noted a clear upregulation of the expression of CD80 and CD86 molecules as well as a slight expression of CD83.
The expression of this last marker is commonly used as the DC maturation marker and, although its function is not completely understood, its expression has been linked with the ability to induce protective immune responses to test antigens in human clinical trials. 41 Also, the production of IL-12 by the ALVAC-infected DC which otherwise remains near control values, was induced after treatment with poly I:C.
Interestingly, our data show that immature DC from HLA-A1 melanoma patients transduced with an ALVAC vector carrying MAGE 1/3 minigenes were capable of activating a MAGE 3/A1 CTL clone more efficiently than same DC loaded with MAGE 3/A1 peptide, as shown by increased IFN-g secretion. Moreover, we found that CTL activation was even obtained with very low efficiency of DC transduction. In agreement, direct immunization with several ALVAC vectors was shown to induce both humoral immunity and CTL responses, implying that these vectors can target both CD4 þ and CD8 þ T cells. 23 Also, strong CD8 þ effector responses requiring CD4 þ T-cell help were detected in HIV-1 þ individuals vaccinated with even a small percentage of mature DC infected with canarypox virus encoding HIV antigens. 38 In accordance too, immature DC infected by recombinant ALVAC encoding MART-1 were recently shown to express and present this melanoma-associated antigen as evidenced by their capacity to stimulate in vitro an HLA-A2 þ , MART-specific CTL clone. 39 The recent discovery of the differential processing of class-I-restricted epitopes of (tumor) antigens by the standard proteasome and the immunoproteasome 42 supports the use of an ALVAC vector carrying MAGE 1/3 minigenes to infect DC. Indeed immature DC carry equal amounts of both, whereas mature DC contain only immunoproteasome. Therefore transferring into DC minigenes encoding only the specific and relevant peptides should lead to better immune responses, not dependent on antigen processing.
Overall, our data may argue on using DC transduced by ALVAC vectors carrying MAGE sequences as a possible strategy in cancer immunotherapy. Canarypox vectors have an excellent profile in Phase I clinical trials and their effectiveness against infectious agents as well as cancer has been suggested both in animals and humans. 43 Combining the properties of ALVAC vectors with the unique properties of DC as APC could enhance antitumor responses, increasing simultaneously their durability and their magnitude. This strategy appears as an attractive approach in cancer immunotherapy, which merits to be clinically investigated in the future.
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